In COVID-19 clinical update #113, Dr. Griffin discusses tocilizumab use in hospitalized Patients, IL-6 inhibitors and mortality, Baricitinib in hospitalized patients, post-infection neurological sequelae, comparative effectiveness of Pfizer and Moderna vaccines, phase 2/3 study of Paxlovid, infection relapse following Paxlovid, pre-hospital administration of Remdesivir, and hospitalization with different variants. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Timing of Tocilizumab Use in Hospitalized Patients (NIH) Interleukin-6 inhibitors reduce mortality (European Journal of Internal Medicine)  Treatment Effect of Baricitinib on Hospitalized Patients (IDSA) Post Infection Neurological Sequelae (Res Square) Comparative Effectiveness of Pfizer and Moderna Vaccines (Nature Commun) Results from Phase 2/3 Study of Paxlovid (Pfizer)  Infection Relapse Following Suppression by Paxlovid (Res Square) Update on Paxlovid Usage (FDA) Availability and Use of Treatments in Outpatients (CDC) Pre-Hospital Administration of Remdesivir (IDSA) Remdesivir and three other drugs for Hospitalized Patients (Lancet) Guidelines on Usage of Anticoagulants (Am Soc Hematol) Different Variants Hospitalization and Morality (Res Square) Contribute to FIMRIC fundraiser at PWB Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 897 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]